TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3–5.8). Quantitative reverse-transcription–polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

[1]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[2]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[3]  T. McNicholas,et al.  NATURAL HISTORY OF LOCALISED PROSTATIC CANCER , 1988, The Lancet.

[4]  John F Ward,et al.  The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. , 2003, The Journal of urology.

[5]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  P. Scardino,et al.  Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. , 2006, The Journal of urology.

[7]  H. Adami,et al.  NATURAL HISTORY OF LOCALISED PROSTATIC CANCER A Population-based Study in 223 Untreated Patients , 1989, The Lancet.

[8]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[9]  B. Trock,et al.  Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.

[10]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .

[11]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[12]  Lennart Franzén,et al.  How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. , 2006, The Journal of urology.

[13]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[14]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[15]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[16]  Juni Palmgren,et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.

[17]  L. Holmberg,et al.  High 10-year survival rate in patients with early, untreated prostatic cancer. , 1992, JAMA.

[18]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[19]  Paul W Dickman,et al.  Natural history of early, localized prostate cancer. , 2004, JAMA.

[20]  Debashis Ghosh,et al.  Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death , 2005, Cancer Epidemiology Biomarkers & Prevention.

[21]  L. Holmberg,et al.  Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. , 1997, JAMA.

[22]  P. Karakiewicz,et al.  25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. , 2006, The Journal of urology.

[23]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.